Vor Biopharma Inc. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Vor Biopharma Inc. stock issued during period, value, stock options exercised for the quarter ending 2021-03-31 was $65.00K, a 51.16% increase year-over-year.
- Vor Biopharma Inc. stock issued during period, value, stock options exercised for the quarter ending 2020-09-30 was $153.00K.
- Vor Biopharma Inc. stock issued during period, value, stock options exercised for the quarter ending 2020-06-30 was $17.00K.
- Vor Biopharma Inc. stock issued during period, value, stock options exercised for the quarter ending 2020-03-31 was $43.00K.
- Vor Biopharma Inc. stock issued during period, value, stock options exercised for fiscal 2020 was $359.00K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2021-03-31 | $65.00K 10-Q · filed 2021-05-06 | |
| 2020-12-31 | $359.00K 10-K · filed 2022-03-14 | |
| 2020-09-30 | $153.00K 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $17.00K 10-Q · filed 2021-11-10 | |
| 2020-03-31 | $43.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |